Wave Initiates Phase 2a WVE-007 Combination Trial for Obesity
CAMBRIDGE, Mass. — September 23, 2026 Wave Life Sciences announced the initiation of a Phase 2a clinical trial evaluating...
GalNAc-siRNA
Advertisement
Tangram Therapeutics Advances TGM-312 Into MASH Patient Cohorts
London, UK, September 3, 2026 Tangram Therapeutics announced that its investigational MASH treatment TGM-312 has progressed into Part B...
Wave Life Sciences Initiates Phase 2a INLIGHT™ Trial of WVE-007 for Obesity and Cardiometabolic Diseases
CAMBRIDGE, Mass., June 24, 2026 Wave Life Sciences announced the initiation of the Phase 2a multidose portion of the...
Tangram Advances TGM-312 With Phase 1/2 CTA Submission
LONDON — November 26, 2025. Tangram Therapeutics has submitted a Clinical Trial Application (CTA) to the UK Medicines and...
Advertisement
